Clinical evidence strategy
Clarify the clinical questions, intended population, use setting, claims, risks, and evidence sources that should guide the program before a study design becomes fixed.
MEDICAL DEVICE CLINICAL CONSULTING
Medical Device Clinical Consulting
Make clinical evidence decisions that fit the device, the claim, the regulatory path, and the market milestone ahead.
Discuss your clinical program →EVIDENCE WITH A PURPOSE
Clinical work should answer the questions that can change the program.
Clinical evidence is not a separate workstream that begins after the device is finished. It affects how a team frames intended use and claims, chooses a regulatory path, plans verification, speaks with investigators, supports reimbursement, and decides what can be said about the product. When those decisions are made in isolation, teams can collect data that is difficult to use, discover a critical gap late, or overbuild a study that does not answer the real question.
Qualira helps medical-device teams turn clinical uncertainty into a focused evidence plan. The work connects the product, use environment, risks, claims, regulatory expectations, and commercial objective, so the team can make a proportionate decision before time and budget are committed to the wrong activity.
WHERE QUALIRA HELPS
Senior clinical support for the evidence decisions that shape market access.
Study planning and design
Develop practical protocols, endpoints, study materials, and operational plans that produce decision-quality evidence while respecting the device and the people who use it.
Study execution support
Support database user-acceptance testing, IRB materials, site selection and activation, monitoring, close-out, and the coordination needed to keep the study connected to its purpose.
Clinical evaluation and lifecycle evidence
Connect clinical evaluation, post-market clinical follow-up, literature, real-world experience, and new findings to the regulatory and quality decisions that follow launch.
FROM EVIDENCE QUESTION TO ACTIONABLE PLAN
Start with what the evidence must make possible.
For one team, the key question may be whether available bench, usability, and clinical information can support a 510(k) position. For another, it may be whether a first-in-human study, a pivotal study, a post-market study, or a clinical evaluation is needed to support an intended purpose in the United States or Europe. The labels differ, but the work begins with the same discipline: understand the device, the people who will use it, the clinical context, the claim the business needs to support, and the decision that depends on the answer.
Qualira helps teams test those assumptions before study activity takes on momentum. That can include reviewing the intended use and claims alongside risk management, the current technical evidence, comparable devices, the regulatory route, and the gaps that remain. The goal is not to make the evidence package larger by default. It is to identify the smallest credible body of evidence that supports the device honestly and gives the program a clear next step.
When a study is the right answer, design choices matter. Eligibility criteria, endpoints, follow-up, data collection, investigator materials, site capabilities, and monitoring plans each determine what the eventual result can say. A protocol should work for the participants and clinical sites, while producing data that can withstand regulatory, scientific, and business scrutiny. Qualira brings the clinical, regulatory, quality, and technical perspectives into the same planning conversation so the study does not create a new disconnect.
THE DECISIONS A CLINICAL PLAN SHOULD CLARIFY
Give every clinical activity a reason to exist.
A clinical program is strongest when the team can explain why each evidence source matters, what it is expected to answer, and how a result will change the next decision. That makes it easier to prioritize work, communicate with leadership and partners, and adapt without losing the regulatory or scientific thread.
What the device must demonstrate
Evidence should reflect the actual device, intended users, use environment, risk profile, and claims. Qualira helps teams define the questions that will make a meaningful difference to the regulatory and market path, rather than relying on a generic study checklist.
Whether existing evidence is enough
Published literature, prior clinical experience, non-clinical testing, usability work, post-market information, and data from comparable devices can each be relevant. The important question is whether the total picture supports the decision at hand, and where it does not.
How to make study results usable
A useful study produces more than a final report. Its protocol, data, deviations, monitoring records, and conclusions need to be understandable, traceable, and aligned with the claims and regulatory rationale the device will carry forward.
How new information changes the plan
Clinical evidence evolves as the device, claims, risk profile, or market strategy evolves. Qualira helps teams assess the impact of a finding or change, keep decision-makers aligned, and determine whether the right response is analysis, additional evidence, a controlled change, or a different path.
A CONNECTED CLINICAL VIEW
Keep clinical, regulatory, quality, and product decisions in the same conversation.
Clinical evidence can quickly become expensive when different functions are working from different assumptions. A product change may affect the study population. A revised claim may create an evidence question. A risk-control decision may need to be reflected in the protocol, investigator instructions, labeling, and future submission. Those links are easier to manage when someone is looking across the program, not only at one deliverable.
Qualira works alongside internal clinical, regulatory, engineering, quality, and leadership teams. Some programs need support from early evidence strategy through execution and close-out. Others need a focused protocol review, clinical evaluation, gap assessment, added senior capacity, or an independent perspective before an important commitment. The engagement should fit the decision in front of the business.
That connected approach helps teams protect options. It lets them identify issues while a study, claim, device design, or market plan can still change, instead of discovering the problem after resources have been committed and the next milestone depends on explaining around it.
View client outcomes →A USEFUL FIRST CONVERSATION
Bring the evidence question that is holding your program back.
What clinical evidence will our intended use, claims, and regulatory path actually require?
Can the evidence we already have support the next decision, or do we have a defined gap?
How should we shape the protocol and study operations so the result will be useful later?
Do we need a long-term clinical partner, focused study support, or a senior review of the plan?
FREQUENTLY ASKED QUESTIONS
Frequently asked questions
When should a medical-device team involve clinical consulting support?
Bring clinical expertise in while the intended use, claims, evidence questions, and development plan can still be shaped. It is also valuable when a team needs to determine whether clinical data are needed, prepare a study, respond to a changed device or market plan, or bring an existing evidence package into a clearer regulatory story.
Does every medical device need a clinical study?
No. The appropriate evidence depends on the device, intended use, claims, risk profile, available non-clinical evidence, regulatory pathway, and the questions that evidence still leaves open. The useful starting point is a disciplined assessment of what a decision-maker needs to see, rather than an assumption that a study is always or never required.
Can Qualira help with both study planning and regulatory strategy?
Yes. Clinical choices are strongest when they remain connected to intended use, claims, risk management, product development, regulatory expectations, and the future submission. Qualira helps teams keep that connection visible from early evidence planning through study conduct and the records that support a market-access decision.
Can Qualira support an active clinical study?
Yes. Support can be tailored to the question in front of the program, including protocol review, study materials, database user-acceptance testing, site selection and activation, monitoring, close-out, clinical evaluation, or senior input when a finding or device change needs a clear response.
What if our existing clinical evidence was not collected for the claim we now want to make?
That is a common and important decision point. Qualira can help assess what the evidence supports today, where the gap is, and whether the right next step is a narrower claim, additional analysis, a focused study, a different evidence source, or a regulatory conversation before the team commits further resources.
TALK WITH QUALIRA